호르몬 피임약 시장 규모, 점유율, 성장 분석 : 제품별, 호르몬별, 연령별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)

Global Hormonal Contraceptive Market size was valued at USD 19.3 billion in 2023 and is poised to grow from USD 20.11 billion in 2024 to USD 27.95 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).

The global hormonal contraceptive market is poised for significant growth, projected to expand at a compound annual growth rate (CAGR) of around 4.5% between 2022 and 2030. This growth is largely fueled by increasing awareness and acceptance of contraceptive methods, a rising incidence of sexually transmitted infections (STIs), and heightened demand for effective family planning solutions. Oral contraceptives dominate the market, particularly combination pills that contain both estrogen and progestin, thanks to their effectiveness and convenience. However, progestin-only pills are gaining traction, anticipated to grow faster due to their minimal side effects, making them ideal for women who cannot use estrogen. Given their limitations in preventing STIs, the concurrent use of condoms remains crucial for protection.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hormonal Contraceptive market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hormonal Contraceptive Market Segmental Analysis

Global Hormonal Contraceptive Market is segmented by Product, Hormones, End User, Age and region. Based on Product, the market is segmented into Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings and Transdermal Patches. Based on Hormones, the market is segmented into Progestin Only Contraceptive and Combined Hormonal Contraceptive. Based on Age, the market is segmented into 15-24 Years, 25-34 Years, 35-44 Years and Above 44 Years. Based on End User, the market is segmented into Hospitals, Household and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hormonal Contraceptive Market

A significant driver of the global hormonal contraceptive market is the rising awareness and acceptance of contraception for family planning purposes. As population levels continue to surge, especially in developing nations, there is an escalating demand for reliable birth control solutions that enable couples to control family size and spacing effectively. This growing recognition of the importance of contraception has resulted in a notable uptick in the utilization of hormonal contraceptives, which are celebrated for their high efficacy in preventing unintended pregnancies while providing a user-friendly and reversible option for individuals seeking to manage their reproductive health.

Restraints in the Global Hormonal Contraceptive Market

The global hormonal contraceptive market faces notable constraints due to various social and cultural factors that hinder women's access to contraceptive methods. In numerous cultures and communities, contraception is often stigmatized, and certain religious doctrines explicitly forbid its use. Furthermore, a significant lack of awareness and education surrounding contraceptive options exists in many areas globally, contributing to diminished demand for such products. These intertwined social and cultural influences can significantly impede market growth, particularly in regions where such factors heavily influence the choices regarding contraceptive usage. Addressing these challenges is crucial for expanding access to hormonal contraceptives worldwide.

Market Trends of the Global Hormonal Contraceptive Market

The global hormonal contraceptive market is witnessing a pronounced shift towards Long-Acting Reversible Contraceptives (LARCs), such as intrauterine devices (IUDs) and subdermal implants, reflecting a significant trend among consumers. These methods offer high efficacy in preventing unintended pregnancies while providing extended duration of use, appealing particularly to younger women and those desiring reliable, low-maintenance contraception. This growing preference is driven by increasing awareness of reproductive health options, enhanced convenience, and the desire for a hassle-free experience. As a result, LARCs are rapidly gaining traction, reshaping the landscape of hormonal contraceptive solutions worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hormonal Contraceptive Market Size by Product & CAGR (2025-2032)

• Market Overview
• Oral Contraceptive Pills
• Injectable Birth Control
• Emergency Contraceptive Pills
• Vaginal Rings
• Transdermal Patches

Global Hormonal Contraceptive Market Size by Hormones & CAGR (2025-2032)

• Market Overview
• Progestin Only Contraceptive
• Combined Hormonal Contraceptive

Global Hormonal Contraceptive Market Size by Age & CAGR (2025-2032)

• Market Overview
• 15-24 Years
• 25-34 Years
• 35-44 Years
• Above 44 Years

Global Hormonal Contraceptive Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Household
• Clinics

Global Hormonal Contraceptive Market Size & CAGR (2025-2032)

• North America (Product, Hormones, End User, Age)
  • US
  • Canada
• Europe (Product, Hormones, End User, Age)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Hormones, End User, Age)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Hormones, End User, Age)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Hormones, End User, Age)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mithra Pharmaceuticals (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agile Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Afaxys, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pregna International Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations